Therapeutic Focus: Pediatrics

Study: Family History Predicts MACE Events in Young Adults with Psoriasis

Researchers investigated the risk of first-time major adverse cardiovascular (CV) events (MACE) in patients with psoriasis with or without a family history of CV disease (CVD). They identified 2,722,375 individuals (including 25,774 and 4504 patients with mild and severe psoriasis) through administrative registers between January 1, 1997, and December 31, 2011.

Mean baseline age was 26.6 years. A family history of CVD was found among 62.4 percent and 66.8 percent of patients with mild and severe psoriasis, respectively. In patients with psoriasis and a family history of CVD, the adjusted incidence rate ratios of MACE were 1.28 (1.12-1.46) and 1.62 (1.14-2.30) for mild and severe disease, respectively. In patients with psoriasis but without a family history of CVD, there was no increased risk of MACE. Researchers concluded that the findings call for an increased focus on a family history of CVD in CV risk assessment of patients with psoriasis.

—http://www.jaad.org/article/S0190-9622(16)01492-4/abstract

Save the Date: 13th World Congress of Pediatric Dermatology

The 13th World Congress of Pediatric Dermatology (WCPD) meeting is scheduled to be held July 6-9, 2017 in Chicago, IL. Hosted by the Society for Pediatric Dermatology, and co-sponsored by the American Academy of Pediatrics, the WCPD will offer first-class education and networking opportunities. For more information, visit pedsderm.net/wcpd.

Crisaborole Topical Ointment 2% for AD

A recent study showed crisaborole topical ointment 2% was well tolerated, with limited systemic exposure under maximal-use conditions in patients ages two years and older. The pharmacokinetics, safety, and efficacy of crisaborole topical ointment 2% (Anacor Pharmaceuticals), a boron-based benzoxaborole PDE4 inhibitor, were evaluated in children with mild-to-moderate atopic dermatitis (AD) in a Phase 1b, open-label, maximal-use study. Crisaborole topical ointment 2% was applied twice daily (dose 3mg/cm2) for 28 days on patients ages 2 to 17 years with extensive AD.

Of 34 patients enrolled, 31 completed the study. Crisaborole was rapidly absorbed, with limited systemic exposure between days 1 and 8. The study found mean ISGA scores declined from 2.65 at baseline to 1.15 at day 29, 47.1 percent of patients achieved treatment success, 64.7 percent of patients achieved ISGA scores of clear or almost clear, and mean severity scores for AD signs and symptoms declined throughout the study.

—http://onlinelibrary.wiley.com/doi/10.1111/pde.12872/full